Navigation Links
Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Date:10/4/2007

Lead Compound Produces Significant LDL-Cholesterol Reduction and Weight

Loss When Combined with Zetia(R) in Hypercholesterolemic Patients

BRIDGEWATER, N.J., Oct. 4 /PRNewswire/ -- Aegerion Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the treatment of cardiovascular and metabolic diseases, today announced final results of Phase II clinical trials involving its lead cholesterol management compound, an MTP-inhibitor, AEGR-733 either alone or in combination with ezetimibe (brand name: Zetia(R)*). The data were presented in two posters at the XVI International Symposium on Drugs Affecting Lipid Metabolism (DALM) (October 4-7, 2007, New York, NY), jointly sponsored by the Weill Cornell Medical College (New York, NY) and the Giovanni Lorenzini Medical Foundation (Milan, Italy and Houston, TX).

In the study measuring LDL-cholesterol (LDL-C, or "bad cholesterol") reduction, patients treated with a combination 10 mg of ezetimibe and 10 mg AEGR-733 experienced LDL-C reductions of 46%. Patients treated with 10 mg of ezetimibe alone experienced a 20% reduction in LDL-C levels. Significantly greater reductions in total cholesterol, non-HDL-cholesterol, Lp(a), and apoB were observed in the group receiving combined AEGR-733 and ezetimibe. There was no difference in the rate of discontinuations between the groups treated with AEGR-733 plus ezetimibe versus those treated with ezetimibe alone.

In a separate analysis of these data, the ability of AEGR-733 alone or in combination with ezetimibe was assessed for its ability to cause weight loss. Over the course of this study, patients were counseled on a low fat/low cholesterol diet but with no emphasis on total calories or weight reduction. Drug treatment consisted of ezetimibe alone (10 mg), AEGR-733 in escalating doses at 5 mg, then 7.5 mg, then 10 mg, or a combination of the two drugs for 12 weeks. Weight was monitored over the course of the study.

By 12 weeks, subjects rec
'/>"/>

SOURCE Aegerion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
3. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
4. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data at Society Of Nuclear Medicine 2007 Annual Meeting
5. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
8. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
9. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
10. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
11. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)..., WEST PALM BEACH, Fla., Nov. 25 /PRNewswire-First...red Americans, especially the 27 million living wi...be all that happy, says audiologist Cindy Beyer. ,...Amex: EAR ), one of America,s largest hearing car...linked hearing loss to stress, frustration, and so...
(Date:11/25/2009)... , NEW YORK, Nov. 25 Reportlink... is available in its catalogue: ,, United Stat... 2015 ,, http://www.reportlinker.com/p0158733...Forecasts-to-2015.html ,, United States Dental..., Summary ,, This report is an essential sou...
(Date:11/25/2009)... , SAN DIEGO, Nov. 25 /PRNewswire-FirstCall/ ...ce company focused on developing products for mini..., announced today that it will host a conference c.../ 2:30 p.m. PT. The conference call will focus on...Company,s products and will include comments from ...
Breaking Medicine Technology:For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 4Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 5Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 6Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 7Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 8Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 9Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 10Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 11Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 12Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 13NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3NuVasive Announces Conference Call and Webcast Regarding Reimbursement 4 2415 million stimulus award creates national consortium for revealing scientific resources 10601 1 2415 million stimulus award creates national consortium for revealing scientific resources 10601 2 2415 million stimulus award creates national consortium for revealing scientific resources 10601 3Developmental drug may help bone fractures heal after radiation exposure 60527 1Delays in Lung Cancer Care More Common in Public Hospitals 60523 1
...studies presented at the National Lipid ...RSIPPANY, N.J., May 30 Daiichi Sankyo, Inc.,annou...ee pivotal studies,demonstrated that the addition ...es treatment regimens can lower A1C in patients wi...analyses included all patients receiving,Welchol i...
...N,PHARMACEUTICALS, INC. (Nasdaq: VION ) today ann...ead anticancer agent Cloretazine(R) (VNP40101M) in...ed in posters at the 2008,American Society of Clin...Illinois., The poster (Abstract #7051) entitled "... III study of high-dose continuous infusion cytosi...
Other Medicine Technology:Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 2Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 3Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 4Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 5Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 6Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting 2Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting 3
(Date:11/26/2009)...on an emotional rollercoaster, study finds , ...it the fear factor meets the jubilant sports fan. ...ially those who root for the winning team -- enjoy...sted match and victory was in doubt, producing fee... this Thanksgiving weekend as you,re glued to the ...
(Date:11/26/2009)...David Kim of the Live Life Again Center, a practic... of a growing number of physicians who are taking...onnect with individuals who are interested in surg.... Dr. Kim is utilizing Facebook to share before-an...with the community. , Dal...
(Date:11/26/2009)...on Communications announces a highly effective and...rs struggling to make an economic recovery. , ...Flu fears is the type of challenge that could send...ding to Dr. David Benton, business growth expert a...stem – The Rfactor Intensive . “Fea...
(Date:11/25/2009)... 25 When most people he...But a chiropractor can also give patients the help... Joint, which is where your jaw (mandible) contact... The most common symptoms associated with TMJ dysf... of the jaw. But many other symptoms can be cause...
(Date:11/25/2009)...f., Nov. 25 Onyx Pharm...that the company will host two investor events in ... 7, 2009 - 9:00 a.m. CT/10:00 a.m. ET ,, Prin...s surrounding carfilzomib in relapsed and/or refra...erican Society of Hematology (ASH) Annual Meeting ...
Breaking Medicine News(10 mins):Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 3Health News:Pharmacist Injects Cure for Ailing Businesses 2Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2
...e the way to new methods for studying and finding ...of death in industrialized countries, according to...at mutations in a molecular channel found in heart...rolled in the cell could lead to new heart disease...
...rprises. They don't scrape and poke. They massage ... prescribe homeopathic remedies//. Of course...nded colleagues sceptical. Sometimes, there's only...ral Medicine Dentists. The important steps come be...
... higher than national guidelines recommend that, i...ening//, according to a study published in the iss...rican Academy of Neurology. The study of 1,...ines. TIA happens when blood flow to part of the b...
...the risk of becoming infected with tuberculosis (T...B disease//, according to an analysis of previousl...ine. About one-third of the world’s populatio...und information in the article. Active tuberculosi...
...nib, marketed by London company AstraZeneca PLC// ... of lung cancer in whom the first-line treatment h... 20 sites. The patients who have a recorded a... line treatment. Says Medical Science Director...
...d with a brain tumor which is at the stem of her b...to approach the doctor who after routine tests rev...ble brain tumor. The doctors have given her three ...r. According to the doctors, there is a 20 % chanc...
Other Medicine News:Health News:Fruit Flies May Pave Way to New Treatments for Age-related Heart Disease 2Health News:Fruit Flies May Pave Way to New Treatments for Age-related Heart Disease 3Health News:Homeopathy and Hypnosis Come to Dentistry 2Health News:Cholesterol in Stroke Patients Exceeds National Guidelines 2Health News:Susceptibility to TB is High Among the Smokers 2
Universal Adaptor Sleeve
...or biatrial stimulation. This is the first implant...ages. The patients benefit from a lasting improvem... against cardiac remodeling. Tupos LA uses biatria...symptomatic and medicine resistant atrial tachycar...
...ronization therapy defibrillator provides ventricu...ization therapy. Features: Independently programma...V) pacing and sensing. Designed to reduce irregula...rhythmias. Designed to maintain atrial-tracked ven...
...ronization therapy defibrillator provides ventricu...ization therapy. Features: Independently programma...V) pacing and sensing. Designed to reduce irregula...rhythmias. Designed to maintain atrial-tracked ven...
Medicine Products: